Table 4.

Descriptive analysis of antineoplastic dose errors

	Underdosage				Overdosage
Percentage of error1	< 10	[10-50[	[50-100]	> 100	< 10	[10-50[	[50-100]	> 100	Total	Frequency of drug prescriptions (%)
Bevacizumab	-	-	2	-	1	-	-	-	3	0.65
Bleomycin	-	-	-	-	-	3	-	-	3	3.1
Bortezomib	1	-	-	-	-	3	1	-	5	3.36
Carboplatin	4	9	1	-	5	14	2	-	35	2.66
Cetuximab	-	-	-	-	-	-	2	-	2	0.99
Cisplatin	-	-	-	-	-	2	1	3	6	5.22
Cyclophosphamide	1	2	1	-	1	2	1	-	8	6.31
Cytarabine	-	1	-	-	-	-	-	-	1	3.23
Dacarbazine	-	-	-	-	-	1	-	-	1	1.71
Docetaxel	-	-	-	-	-	2	-	1	3	2.69
Doxorubicin	-	-	1	-	2	-	-	1	4	8.04
Drug in clinical trial	-	-	1	-	-	1	-	-	2	0.5
Liposomal doxorubicin	-	-	-	-	-	2	-	-	2	0.31
Epirubicin	-	-	1	-	-	-	-	-	1	0.6
Etoposide	1	1	-	-	1	1	-	1	5	7.82
Fluorouracil	4	-	1	-	4	9	1	-	19	12.1
Gemcitabine	-	1	-	-	-	5	3	1	10	4.91
Ifosfamide	-	2	2	-	2	2	-	-	8	2.67
Irinotecan	1	-	-	-	1	1	-	1	4	2.57
Methotrexate	-	-	1	-	-	1	-	-	2	1.6
Oxaliplatin	1	2	-	-	1	7	1	1	13	2.15
Paclitaxel	1	-	-	-	-	3	-	-	4	1.63
Raltitrexed	-	-	-	-	-	-	1	-	1	0.1
Rituximab	-	2	-	-	4	-	1	-	7	8.21
Trastuzumab	-	1	1	-	-	-	-	-	2	1.78
Vinblastine	-	-	-	-	1	1	-	1	3	2.01
Vincristine	-	-	-	-	1	4	3	-	8	5.18
Vindesine	-	-	-	-	1	-	-	-	1	0.75
Vinorelbine	-	-	-	-	-	2	1	1	4	2.12
Total	14	21	12	-	25	66	18	11	167

¹ Percentage of error = (theoretical dose - incorrect dose)/theoretical dose *100